German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer.
Chemotherapy
Gastric cancer
Immunotherapy
Neoadjuvant
Perioperative
Targeted therapy
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
08
06
2023
accepted:
07
08
2023
medline:
4
1
2024
pubmed:
17
10
2023
entrez:
17
10
2023
Statut:
ppublish
Résumé
The updated edition of the German, Austrian and Swiss Guidelines for Systemic Treatment of Gastric Cancer was completed in August 2023, incorporating new evidence that emerged after publication of the previous edition. It consists of a text-based "Diagnosis" part and a "Therapy" part including recommendations and treatment algorithms. The treatment part includes a comprehensive description regarding perioperative and palliative systemic therapy for gastric cancer and summarizes recommended standard of care for surgery and endoscopic resection. The guidelines are based on a literature search and evaluation by a multidisciplinary panel of experts nominated by the hematology and oncology scientific societies of the three involved countries.
Identifiants
pubmed: 37847333
doi: 10.1007/s10120-023-01424-y
pii: 10.1007/s10120-023-01424-y
pmc: PMC10761449
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6-18Informations de copyright
© 2023. The Author(s).
Références
AWMF S3 guideline. Gastric carcinoma. Diagnosis and therapy of adenocarcinomas of the stomach and esophagogastric junction. 2019. http://www.awmf.org/leitlinien/detail/ll/032-009OL.html
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–4 (PMID:14320675).
doi: 10.1111/apm.1965.64.1.31
pubmed: 14320675
Parsonnet J, Vandersteen D, Goates J, et al. Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas. J Natl Cancer Inst. 1991;83:640–3 (PMID:2023282).
doi: 10.1093/jnci/83.9.640
pubmed: 2023282
Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors. In: Wittekind C, editor. Wiley-Blackwell. USA; 2016.
The Cancer Genome Atlas. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9. https://doi.org/10.1038/nature13480 .
doi: 10.1038/nature13480
Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435–42. https://doi.org/10.1200/JCO.2007.13.9378 .
doi: 10.1200/JCO.2007.13.9378
pubmed: 18349393
Chen CY, Hsu JS, Wu DC, et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT-correlation with surgical and histopathologic results. Radiology. 2007;242:472–82. https://doi.org/10.1148/radiol.2422051557 .
doi: 10.1148/radiol.2422051557
pubmed: 17255419
Kwee R, Kwee T. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12:6–22. https://doi.org/10.1007/s10120-008-0492-5 .
doi: 10.1007/s10120-008-0492-5
pubmed: 19390927
Catalano MF, Sivak MV Jr, Rice T, et al. Endosonographic features predictive of lymph node metastasis. Gastrointest Endosc. 1994;40:442–6 (PMID:7926534).
doi: 10.1016/S0016-5107(94)70206-3
pubmed: 7926534
Bennett C, Wang Y, Pan T. Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev. 2009;4:004276. https://doi.org/10.1002/14651858.CD004276.pub3 .
doi: 10.1002/14651858.CD004276.pub3
Tada M, Tanaka Y, Matsuo N, et al. Mucosectomy for gastric cancer: current status in Japan. J Gastroenterol Hepatol. 2000;15(Suppl):D98-102 (PMID:10759227).
doi: 10.1046/j.1440-1746.2000.02137.x
pubmed: 10759227
National Cancer Institute: Surveillance, Epidemiology and End Results. https://seer.cancer.gov/statfacts/html/stomach.html
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20. https://doi.org/10.1056/NEJMoa055531 .
doi: 10.1056/NEJMoa055531
pubmed: 16822992
Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21. https://doi.org/10.1200/JCO.2010.33.0597 .
doi: 10.1200/JCO.2010.33.0597
pubmed: 21444866
Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57. https://doi.org/10.1016/S0140-6736(18)32557-1 .
doi: 10.1016/S0140-6736(18)32557-1
pubmed: 30982686
Hofheinz RD, Merx K, Haag GM, et al. FLOT versus FLOT/trastuzumab/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group. J Clin Oncol. 2022;40:3750–61. https://doi.org/10.1200/JCO.22.00380 .
doi: 10.1200/JCO.22.00380
pubmed: 35709415
Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37:3392–400. https://doi.org/10.1200/JCO.19.01124 .
doi: 10.1200/JCO.19.01124
pubmed: 31513484
Al-Batran SE, Lorenzen S, Homann N, et al. Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK. Ann Oncol. 2021;32(5):1040–75. https://doi.org/10.1016/j.annonc.2021.08.1538 .
doi: 10.1016/j.annonc.2021.08.1538
André T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41:255–65. https://doi.org/10.1200/JCO.22.00686 .
doi: 10.1200/JCO.22.00686
pubmed: 35969830
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635–48. https://doi.org/10.1016/S0140-6736(20)31288-5 .
doi: 10.1016/S0140-6736(20)31288-5
pubmed: 32861308
Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:004064. https://doi.org/10.1002/14651858.CD004064.pub4 .
doi: 10.1002/14651858.CD004064.pub4
Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46. https://doi.org/10.1056/NEJMoa073149 .
doi: 10.1056/NEJMoa073149
pubmed: 18172173
Okines AFC, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced esophago-gastric cancer. Ann Oncol. 2009;20:1529–34. https://doi.org/10.1093/annonc/mdp047 .
doi: 10.1093/annonc/mdp047
pubmed: 19474114
Cassidy J, Saltz L, Twelves C, et al. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol. 2011;22:2604–9. https://doi.org/10.1093/annonc/mdr031 .
doi: 10.1093/annonc/mdr031
pubmed: 21415237
Ajani JA, Abramov M, Bondarenko I, et al. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017;28:2142–8. https://doi.org/10.1093/annonc/mdx275 .
doi: 10.1093/annonc/mdx275
pubmed: 28911091
Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21. https://doi.org/10.1016/S1470-2045(08)70035-4 .
doi: 10.1016/S1470-2045(08)70035-4
pubmed: 18282805
Hall PS, Swinson D, Cairns DA, et al. Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial. JAMA Oncol. 2021;7:869–77. https://doi.org/10.1001/jamaoncol.2021.0848 .
doi: 10.1001/jamaoncol.2021.0848
pubmed: 33983395
pmcid: 8120440
Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7. https://doi.org/10.1200/JCO.2006.06.8429 .
doi: 10.1200/JCO.2006.06.8429
pubmed: 17075117
Lorenzen S, Hentrich M, Haberl C, et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007;18:1673–9. https://doi.org/10.1093/annonc/mdm269 .
doi: 10.1093/annonc/mdm269
pubmed: 17660494
Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19:1882–7. https://doi.org/10.1093/annonc/mdn403 .
doi: 10.1093/annonc/mdn403
pubmed: 18669868
Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. J Clin Oncol. 2015;33:3874–9. https://doi.org/10.1200/JCO.2015.60.7465 .
doi: 10.1200/JCO.2015.60.7465
pubmed: 26438119
Van Cutsem E, Boni C, Tabernero J, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol. 2015;26:149–56. https://doi.org/10.1093/annonc/mdu496 .
doi: 10.1093/annonc/mdu496
pubmed: 25416687
Yamada Y, Boku N, Mizusawa J, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4:501–10. https://doi.org/10.1016/S2468-1253(19)30083-4 .
doi: 10.1016/S2468-1253(19)30083-4
pubmed: 31101534
Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450–7. https://doi.org/10.1093/annonc/mdn166 .
doi: 10.1093/annonc/mdn166
pubmed: 18558665
Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32:3520–6. https://doi.org/10.1200/JCO.2013.54.1011 .
doi: 10.1200/JCO.2013.54.1011
pubmed: 25287828
Lordick F, Al-Batran SE, Dietel M, et al. HER2 testing in gastric cancer: results of a German expert meeting. J Cancer Res Clin Oncol. 2017;143:835–41. https://doi.org/10.1007/s00432-017-2374-x .
doi: 10.1007/s00432-017-2374-x
pubmed: 28285403
pmcid: 5384945
Haffner I, Schierle K, Raimúndez E, et al. HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study. J Clin Oncol. 2021;39:1468–78. https://doi.org/10.1200/JCO.20.02761 .
doi: 10.1200/JCO.20.02761
pubmed: 33764808
pmcid: 8099392
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97. https://doi.org/10.1016/S0140-6736(10)61121-X .
doi: 10.1016/S0140-6736(10)61121-X
pubmed: 20728210
Ryu MH, Yoo C, Kim JG, et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer. 2015;51:482–8. https://doi.org/10.1016/j.ejca.2014.12.015 .
doi: 10.1016/j.ejca.2014.12.015
pubmed: 25661103
Rivera F, Romero C, Jimenez-Fonseca P, et al. Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol. 2019;83:1175–81. https://doi.org/10.1007/s00280-019-03820-7 .
doi: 10.1007/s00280-019-03820-7
pubmed: 30927036
pmcid: 6779679
Takahari D, Chin K, Ishizuka N, et al. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer. Gastric Cancer. 2019;22:1238–46. https://doi.org/10.1007/s10120-019-00973-5 .
doi: 10.1007/s10120-019-00973-5
pubmed: 31102009
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40. https://doi.org/10.1016/S0140-6736(21)00797-2 .
doi: 10.1016/S0140-6736(21)00797-2
pubmed: 34102137
pmcid: 8436782
Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234–47. https://doi.org/10.1016/S1470-2045(21)00692-6 .
doi: 10.1016/S1470-2045(21)00692-6
pubmed: 35030335
Rha SY, Wyrwicz LS, Weber PEY, et al. Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction cancer: phase III KEYNOTE-859 study. Ann Oncol. 2023;34:P319-320. https://doi.org/10.1016/j.annonc.2023.01.006 .
doi: 10.1016/j.annonc.2023.01.006
Sun JM, Shen L, Shah MA, et al. Keynote-590 Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase study. Lancet. 2021;398:759–71. https://doi.org/10.1016/S0140-6736(21)01234-4 .
doi: 10.1016/S0140-6736(21)01234-4
pubmed: 34454674
Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study. Ann Oncol. 2021;32:1331. https://doi.org/10.1016/j.annonc.2021.08.2133 .
doi: 10.1016/j.annonc.2021.08.2133
Möhler MH, Kato K, Arkenau HT, et al. Rationale 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). J Clin Oncol. 2023;41:286. https://doi.org/10.1200/JCO.2023.41.4_suppl.286 .
doi: 10.1200/JCO.2023.41.4_suppl.286
Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN182-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase trial. Lancet. 2023;401:1655–68. https://doi.org/10.1016/S0140-6736(23)00620-7 .
doi: 10.1016/S0140-6736(23)00620-7
pubmed: 37068504
Xu RH, Shitara K, Ajani JA, et al. Zolbetuximab + CAPOX in 1L claudin-182+/HER2- locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: Primary phase 3 results from GLOW. J Clin Oncolo. 2023. https://doi.org/10.1200/JCO.2023.41.36_suppl.405736 .
doi: 10.1200/JCO.2023.41.36_suppl.405736
Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47:2306–14. https://doi.org/10.1016/j.ejca.2011.06.002 .
doi: 10.1016/j.ejca.2011.06.002
pubmed: 21742485
Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438–44. https://doi.org/10.1200/JCO.2012.48.5805 .
doi: 10.1200/JCO.2012.48.5805
pubmed: 24190112
Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78–86. https://doi.org/10.1016/S1470-2045(13)70549-7 .
doi: 10.1016/S1470-2045(13)70549-7
pubmed: 24332238
Brown J, Liepa AM, Bapat B, et al. Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom. Eur J Cancer Care. 2020;29:e13213. https://doi.org/10.1111/ecc.13213 .
doi: 10.1111/ecc.13213
Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35. https://doi.org/10.1016/S1470-2045(14)70420-6 .
doi: 10.1016/S1470-2045(14)70420-6
pubmed: 25240821
Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9. https://doi.org/10.1016/S0140-6736(13)61719-5 .
doi: 10.1016/S0140-6736(13)61719-5
pubmed: 24094768
Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123–33. https://doi.org/10.1016/S0140-6736(18)31257-1 .
doi: 10.1016/S0140-6736(18)31257-1
pubmed: 29880231
Chao J, Fuchs CS, Shitara K, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7:895–902. https://doi.org/10.1001/jamaoncol.2021.0275 .
doi: 10.1001/jamaoncol.2021.0275
pubmed: 33792646
pmcid: 8017478
Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353–65. https://doi.org/10.1016/S1470-2045(20)30445-9 .
doi: 10.1016/S1470-2045(20)30445-9
pubmed: 32919526
St K, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;9:1449–58. https://doi.org/10.1038/s41591-018-0101-z .
doi: 10.1038/s41591-018-0101-z
Gu L, Chen M, Guo D, et al. PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis. PLoS ONE. 2017;12:e0182692. https://doi.org/10.1371/journal.pone.0182692 .
doi: 10.1371/journal.pone.0182692
pubmed: 28796808
pmcid: 5552131
Massetti M, Lindinger M, Lorenzen S. PD-1 blockade elicits ongoing remission in two cases of refractory Epstein-Barr virus associated metastatic gastric carcinoma. Oncol Res Treat. 2022;45:375–9. https://doi.org/10.1159/000523754 .
doi: 10.1159/000523754
Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). J Clin Oncol. 2020;38:1919–27. https://doi.org/10.1200/JCO.19.03077 .
doi: 10.1200/JCO.19.03077
pubmed: 32208960
Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase III study. J Clin Oncol. 2014;32:2039–49. https://doi.org/10.1200/JCO.2013.53.6136 .
doi: 10.1200/JCO.2013.53.6136
pubmed: 24868024
Lorenzen S, Riera Knorrenschild J, Haag GM, et al. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastroesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer. 2015;51:569–76. https://doi.org/10.1016/j.ejca.2015.01.059 .
doi: 10.1016/j.ejca.2015.01.059
pubmed: 25694417
Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 trial. Lancet Oncol. 2017;18:640–53. https://doi.org/10.1016/S1470-2045(17)30111-0 .
doi: 10.1016/S1470-2045(17)30111-0
pubmed: 28343975
Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–30. https://doi.org/10.1056/NEJMoa2004413 .
doi: 10.1056/NEJMoa2004413
pubmed: 32469182
Ku GY, Di Bartolomeo M, Smyth E, et al. Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in Western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimens. Ann Oncol. 2022;33:S555–80. https://doi.org/10.1016/annonc/annonc1065 .
doi: 10.1016/annonc/annonc1065
Yamaguchi K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial. J Clin Oncol. 2023;41:816–25. https://doi.org/10.1200/JCO.22.00575 .
doi: 10.1200/JCO.22.00575
pubmed: 36379002
Shitara K, Do T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase trial. Lancet Oncol. 2018;19:1437–48.
doi: 10.1016/S1470-2045(18)30739-3
pubmed: 30355453
Ilson DH, Tabernero J, Prokharau A, et al. Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: subgroup analyses of a randomized clinical trial. JAMA Oncol. 2020;6:e193531. https://doi.org/10.1001/jamaoncol.2019.3531 .
doi: 10.1001/jamaoncol.2019.3531
pubmed: 31600365
Tabernero J, Shitara K, Zaanan A, et al. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. ESMO Open. 2021;6:100200. https://doi.org/10.1016/j.esmoop.2021.100200 .
doi: 10.1016/j.esmoop.2021.100200
pubmed: 34175675
pmcid: 8253956
Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71. https://doi.org/10.1016/S0140-6736(17)31827-5 .
doi: 10.1016/S0140-6736(17)31827-5
pubmed: 28993052
Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29:1895–902. https://doi.org/10.1093/annonc/mdy263 .
doi: 10.1093/annonc/mdy263
pubmed: 30137196
pmcid: 6158764
Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309–18. https://doi.org/10.1016/S1470-2045(15)00553-7 .
doi: 10.1016/S1470-2045(15)00553-7
pubmed: 26822397
Markar SR, Mikhail S, Malietzis G, et al. Influence of surgical resection of hepatic metastases from gastric adenocarcinoma on long-term survival: systematic review and pooled analysis. Ann Surg. 2016;263:1092–101. https://doi.org/10.1097/SLA.00000000001542 .
doi: 10.1097/SLA.00000000001542
pubmed: 26797324
Kataoka K, Kinoshita T, Moehler M, et al. Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. Gastric Cancer. 2017;20:904–12. https://doi.org/10.1007/s10120-017-0696-7 .
doi: 10.1007/s10120-017-0696-7
pubmed: 28150070
Kroese TE, van Hillegersberg R, Schoppmann S, et al. OMEC working group. Definitions and treatment of oligometastatic esophagogastric cancer according to multidisciplinary tumor boards in Europe. Eur J Cancer. 2022;164:18–29. https://doi.org/10.1016/j.ejca.2021.11.032 .
doi: 10.1016/j.ejca.2021.11.032
pubmed: 35134666
Al-Batran SE, Homann N, Pauligk C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: The AIO-FLOT3 Trial. JAMA Oncol. 2017;3:1237–44. https://doi.org/10.1001/jamaoncol.2017.0515 .
doi: 10.1001/jamaoncol.2017.0515
pubmed: 28448662
pmcid: 5824287
Lu Z, Fang Y, Liu C, et al. Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer: a phase III randomized controlled trial. J Clin Oncol. 2021;39:748–56. https://doi.org/10.1200/JCO.20.01254 .
doi: 10.1200/JCO.20.01254
pubmed: 33417481
pmcid: 8078238
Mansoor W, Roeland EJ, Chaudhry A, et al. Early weight loss as a prognostic factor in patients with advanced gastric cancer: analyses from REGARD, RAINBOW, and RAINFALL phase III studies. Oncologist. 2021;26:e1538–47. https://doi.org/10.1002/onco.13836 .
doi: 10.1002/onco.13836
pubmed: 34037286
pmcid: 8417853
Hacker UT, Hasenclever D, Linder N, et al. Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial. J Cachexia Sarcop Muscle. 2020;11:135–44. https://doi.org/10.1002/jcsm.12484 .
doi: 10.1002/jcsm.12484
Hacker UT, Hasenclever D, Baber R, et al. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. Ann Oncol. 2022;33:685–92. https://doi.org/10.1016/j.annonc.2022.03.274 .
doi: 10.1016/j.annonc.2022.03.274
pubmed: 35395383
Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. Educational and clinical practice committee, European society of parenteral and enteral nutrition (ESPEN). ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003;22:415–21. https://doi.org/10.1016/s0261-5614(03)00098-0 .
doi: 10.1016/s0261-5614(03)00098-0
pubmed: 12880610
Dai Y, Li C, Xie Y, et al. Interventions for dysphagia in esophageal cancer. Cochrane Database Syst Rev. 2014;10:005048. https://doi.org/10.1002/14651858.CD005048.pub4 .
doi: 10.1002/14651858.CD005048.pub4
Bergquist H, Wenger U, Johnsson E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction Results of a randomized, controlled clinical trial. Dis Esophagus. 2005;18:131–9. https://doi.org/10.1111/j.1442-2050.2005.00467.x .
doi: 10.1111/j.1442-2050.2005.00467.x
pubmed: 16045572
Mulazzani GEG, Corti F, Della Valle S, Di Bartolomeo M. Nutritional support indications in gastroesophageal cancer patients: from perioperative to palliative systemic therapy A comprehensive review of the last decade. Nutrients. 2021;13:2766. https://doi.org/10.3390/nu13082766 .
doi: 10.3390/nu13082766
pubmed: 34444926
pmcid: 8400027
Jamel S, Markar SR, Malietzis G, et al. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis. Gastric Cancer. 2018;21:10–8. https://doi.org/10.1007/s10120-017-0749-y .
doi: 10.1007/s10120-017-0749-y
pubmed: 28779261
Lauwers GY, Carneiro F, Graham DY. Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of tumours of the digestive system. Lyon: IARC; 2010.